Senti Biosciences's three largest insider shareholders as of April 17, 2026 are Partners Spv 24 Celadon (TenPercentOwner, 9.78Mn shares), Enterprise Associates 15, L.P. New (TenPercentOwner, 3.78Mn shares), Enterprise Associates 15, L.P. New (TenPercentOwner, 3.78Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Partners Spv 24 Celadon | - | 9,777,000 | 0 | 14 Mar, 2025 |
| Enterprise Associates 15, L.P. New | - | 3,775,615 | 0 | 12 Mar, 2025 |
| Enterprise Associates 15, L.P. New | - | 3,775,615 | 0 | 12 Mar, 2025 |
| Enterprise Associates 15, L.P. New | - | 3,775,615 | 0 | 12 Mar, 2025 |
| Enterprise Associates 15, L.P. New | - | 3,775,615 | 0 | 12 Mar, 2025 |
| Healthcare Llc Bayer | - | 2,809,848 | 0 | 12 Mar, 2025 |
| Healthcare Llc Bayer | - | 2,809,848 | 0 | 12 Mar, 2025 |
| Healthcare Llc Bayer | - | 2,809,848 | 0 | 12 Mar, 2025 |
| Timothy K Lu | Ceo | 639,583 | 0 | 09 Mar, 2026 |
| Deborah Knobelman | Chief Financial Officer | 131,000 | 0 | 02 Feb, 2024 |
| Kanya Rajangam | Pres. Chief Med. Dev. Off. | 74,843 | 0 | 09 Mar, 2026 |
| Kanya Rajangam | Pres. Chief Med. Dev. Off. | 0 | 33,000 | 11 Mar, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Mar, 2026 | Timothy K Lu | Common Stock | D | 80,666 | $0.00 | 639,583 | D | F |
| 09 Mar, 2026 | Kanya Rajangam | Common Stock | D | 10,757 | $0.00 | 74,843 | D | F |
| 02 Feb, 2026 | Timothy K Lu | Common Stock | D | 4,191 | $0.00 | 720,249 | D | F |
| 02 Feb, 2026 | Kanya Rajangam | Common Stock | D | 1,384 | $0.00 | 85,600 | D | F |
| 18 Jul, 2025 | Bryan Daniel Baum | Stock Option (Right to Buy) | A | 43,900 | $0.00 | 43,900 | D | A |
| 25 Jun, 2025 | James J. Collins | Stock Option (Right to Buy) | A | 21,950 | $0.00 | 21,950 | D | A |
| 25 Jun, 2025 | Edward T Mathers | Stock Option (Right to Buy) | A | 21,950 | $0.00 | 21,950 | D | A |
| 25 Jun, 2025 | Brenda Cooperstone | Stock Option (Right to Buy) | A | 21,950 | $0.00 | 21,950 | D | A |
| 25 Jun, 2025 | Feng Hsiung | Stock Option (Right to Buy) | A | 21,950 | $0.00 | 21,950 | D | A |
| 25 Jun, 2025 | Fran Schulz | Stock Option (Right to Buy) | A | 21,950 | $0.00 | 21,950 | D | A |
| 10 Mar, 2025 | Partners Spv 24 Celadon | Common Stock | A | 9,777,000 | - | 9,777,000 | D | C |
| 10 Mar, 2025 | Partners Spv 24 Celadon | Series A Convertible Preferred Stock | D | 9,777 | - | 0 | D | C |
| 10 Mar, 2025 | Healthcare Llc Bayer | Common Stock | A | 2,222,000 | - | 2,809,848 | D | C |
| 10 Mar, 2025 | Enterprise Associates 15, L.P. New | Common Stock | A | 3,333,000 | - | 3,775,615 | D | C |
| 10 Mar, 2025 | Healthcare Llc Bayer | Series A Convertible Preferred Stock | D | 2,222 | - | 0 | D | C |
| 10 Mar, 2025 | Enterprise Associates 15, L.P. New | Series A Convertible Preferred Stock | D | 3,333 | - | 0 | D | C |
| 07 Mar, 2025 | Brenda Cooperstone | Stock Option (Right to Buy) | A | 43,900 | $0.00 | 43,900 | D | A |
| 07 Mar, 2025 | Feng Hsiung | Stock Option (Right to Buy) | A | 43,900 | $0.00 | 43,900 | D | A |
| 07 Mar, 2025 | Edward T Mathers | Stock Option (Right to Buy) | A | 43,900 | $0.00 | 43,900 | D | A |
| 07 Mar, 2025 | Fran Schulz | Stock Option (Right to Buy) | A | 43,900 | $0.00 | 43,900 | D | A |